Do you think GeneDx will be sold seperately or go with the bioreference sale? Could GeneDx stand alone on it's own from a revenue and internal systems viewpoint?
It could stand on its own, however, opko bought the company for the clinical operations to sell 4K. So I would say it's more likely both units will be sold together.
I was thinking bigger, like all of opko being sold to someone like Pfizer. A big pharma company may have better luck pushing 4k to the masses, they have an army of lobbyists
